Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 7, 2012, Pages 1076-1083

  Kim, Tae Hyung ^a   Park, Chan Woong ^a   Kim, Hoi Yun ^a   Chi, Moon Hyuk ^a   Lee, Sung Kyung ^a   Song, Young Me ^a   Jiang, Hai Hua ^a   Lim, Sung Mook ^a   Youn, Yu Seok ^a   Lee, Kang Choon ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Exendin 4; Hypoglycemic effect; Intranasal administration; PEGylation; Type 2 diabetes

Indexed keywords

EXENDIN 4; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INTRANASAL; ANIMALS; DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; PEPTIDES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; VENOMS;

EID: 84863557889     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00029     Document Type: Article

References (31)

1. Cefalu WT. Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care, 27, 239-246 (2004).
2. Chien YW, Chang SF. Intranasal drug delivery for systemic medications. Crit. Rev. Ther. Drug Carrier Syst., 4, 67-194 (1987).
3. Pontiroli AE. Peptide hormones: Review of current and emerging uses by nasal delivery. Adv. Drug Deliv. Rev., 29, 81-87 (1998).
4. Pontiroli AE, Calderara A, Pozza G. Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective. Clin. Pharmacokinet., 17, 299-307 (1989).
5. Illum L. Nasal delivery of peptides, factors affecting nasal absorption. Topics in pharmaceutical sciences. (Crommelin DJA, Midha KK eds.), Medpharm Scientific Publishers, Sttutgart, pp. 71-82 (1992).
6. Nagai T, Suzuki Y. Therapeutic possibilities for nasal delivery. Topics in pharmaceutical sciences. (Crommelin DJA, Midha KK eds.), Medpharm Scientific Publishers, Sttutgart, pp. 82-93 (1992).
7. McMartin C, Hutchinson LE, Hyde R, Peters GE. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci., 76, 535-540 (1987).
8. Sarkar MA. Drug metabolism in the nasal mucosa. Pharm. Res., 9, 1-9 (1992).
9. Lee VH. Enzymatic barriers to peptide and protein absorption. Crit. Rev. Ther. Drug Carrier Syst., 5, 69-97 (1988).
10. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem., 267, 7402-7405 (1992).
11. Gallwitz B. New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev. Diabet. Stud., 2, 61-69 (2005).
12. Todd JF, Bloom SR. Incretins and other peptides in the treatment of diabetes. Diabet. Med., 24, 223-232 (2007).
13. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 368, 1696-1705 (2006).
14. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab., 88, 3082-3089 (2003).
15. Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, Parkes DG, Young AA. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int. J. Pharm., 356, 231-238 (2008).
16. Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical protein. Pharm. Sci. Technol. Today, 1, 352-356 (1998).
17. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov., 2, 214-221 (2003).
18. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today, 10, 1451-1458 (2005).
19. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev., 55, 1261-1277 (2003).
20. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet., 40, 539-551 (2001).
21. Lee KC, Park MO, Na DH, Youn YS, Lee SD, Yoo SD, Lee HS, DeLuca PP. Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats. Calcif. Tissue Int., 73, 545-549 (2003).
22. Youn YS, Jeon JE, Chae SY, Lee S, Lee KC. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagonlike peptide-1 in type 2 diabetic db/db mice. Diabetes Obes. Metab., 10, 343-346 (2008).
23. Chae SY, Jin CH, Shin JH, Son S, Kim TH, Lee S, Youn YS, Byun Y, Lee MS, Lee KC. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J. Control. Release, 142, 206-213 (2010).
24. Chae SY, Choi YG, Son S, Jung SY, Lee DS, Lee KC. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. J. Control. Release, 144, 10-16 (2010).
25. Kim I, Kim TH, Ma K, Lee ES, Kim D, Oh KT, Lee DH, Lee KC, Youn YS. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy. Bioconjug. Chem., 21, 1513-1519 (2010).
26. Kim TH, Jiang HH, Youn YS, Park CW, Lim SM, Jin CH, Tak KK, Lee HS, Lee KC. Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution. J. Pharm. Sci., 100, 482-491 (2011).
27. Romeo VD, deMeireles JC, Gries WJ, Xia WJ, Sileno AP, Pimplaskar HK, Behl CR. Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv. Drug Deliv. Rev., 29, 117-133 (1998).
28. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem., 268, 19650-19655 (1993).
29. Lee S, Youn YS, Lee SH, Byun Y, Lee KC. PEGylated glucagonlike peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia, 49, 1608-1611 (2006).
30. Al-Sabah S, Donnelly D. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. Br. J. Pharmacol., 140, 339-346 (2003).
31. Donovan MD, Flynn GL, Amidon GL. Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm. Res., 7, 863-868 (1990).